TMCnet News
iCareDx Announces Appointment Of Advisory BoardiCareDx, Inc., a biotechnology company focused on blood-based early detection of cancer, today announced the formation of an Advisory Board, comprised of renowned scientists, clinicians and business leaders in the areas of oncology and diagnostics. The Advisory Board's role will be to provide valuable scientific, clinical and business insights, along with strategic guidance in decision-making, as the Company seeks to advance its blood-based screening tests for early detection of colorectal cancer as well as for early detection in pan-oncology. "We are honored to welcome such outstanding authorities in their respective areas to our advisory board to support the development of iCareDx's early detection screening technologies," said Dr. Bernard Peperstraete, the Chief Executive Officer of iCareDx. "In forming the company's inaugural Advisory Board, we are seeking to further position iCareDx to successfully pursue a highly accurate and cost-effective approach for early cancer detection, and to ultimately help reduce cancer deaths." Over the past years, the design of iCareDx's molecular detection technologies was led by Francis Barany, PhD, Professor of Microbiology and Immunology at the Weill Cornell Medicine. Dr. Barany is a prolific inventor with 52 issued US patents, which are foundational inventions in molecular diagnostics and next generation sequencing, and include the ligase chain reaction (LCR), the ligase detection reaction (LDR), and the Universal DNA array. "We have assembled this team of thought leaders to guide our efforts in advancing our platform for blood-based early cancer detection," said Dr. Francis Barany. "Our scalable, low-cost cancer detection platforms are designed to vastly improve cancer care, ultimately throughout the world." Composition of iCareDx's Advisory Board:
iCareDx is a biotechnology company focused on developing technologies for blood-based early detection of cancer. iCareDx's technology allows for highly accurate screening of blood to detect cancer markers at the early cancer stages, before the cancer becomes untreatable. Backed by a highly experienced team, it is iCareDx's mission to contribute to the global battle against cancer by detecting and attacking cancer through high-precision, early detection. For more information, please visit www.icaredx.com, or contact us at [email protected]. View source version on businesswire.com: http://www.businesswire.com/news/home/20160516006730/en/ |